Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Standard BioTools Inc.NASDAQ: LAB

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $2.12M fell 61.1% year over year, behind the -43.6% change in trailing-twelve-month research & development. Sequentially, it fell 72.8% from the prior quarter. Over 3 fiscal years it compounded at -11.4% a year.

Context

  • Research & development amounted to 30.5% of revenue in FY2025, down 5.3 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -61.1% toward the trailing-twelve-month pace of -43.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.12M-72.8% QoQ
Last fiscal yearDec 2025
$25.99M-58.4% YoY
LTMMar 2026
$22.48M-43.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-61.1%——
1 year-58.4%——
3-year CAGR-11.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
25.99M USD
Year-over-year change
-58.4%
4-year CAGR
-9.0%

Research & Development vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -43.6% is the lowest of 11, against a peer median of -7.5%.
  • Research & development amounts to 26.1% of revenue for LAB, versus a peer median of 9.3%.
LAB Competitors
Research & Development for LAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$188.07M USD+22.3%+26.8%—
SYSo-Young International Inc.LTM Mar 2026CN¥128.61M CNY-18.4%-17.2%7.8%
ADCTADC Therapeutics S.A.LTM Mar 2026$94.95M USD-15.8%-17.7%119.9%
VREXVarex Imaging CorporationLTM Apr 2026$89.5M USD+0.1%+5.8%10.4%
CTKBCytek Biosciences, Inc.LTM Mar 2026$36.35M USD-7.6%+1.5%17.8%
AVNSAvanos Medical, Inc.LTM Mar 2026$22.9M USD-6.9%-8.9%3.2%
LABStandard BioTools Inc.LTM Mar 2026$22.48M USD-43.6%-11.4%26.1%
CBLLCeriBell, Inc.LTM Mar 2026$21.06M USD+43.4%+38.3%22.2%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$19.34M USD-7.4%+14.3%9.3%
BVSBioventus Inc.LTM Mar 2026$11.57M USD-19.0%-20.2%2.0%
KIDSOrthoPediatrics Corp.LTM Mar 2026$8.98M USD-13.5%+2.5%3.7%
Peer median (excluding LAB) —-7.5%+2.0%9.3%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.58M97.95M106.34M174.43M85.33M
Cost of Revenue61.21M60.9M55.89M90.17M42.79M
Gross Profit69.37M37.05M50.45M84.26M42.54M
Gross Margin53.1%37.8%47.4%48.3%49.9%
Research & Development37.94M37.38M25.95M62.41M25.99M
Selling, General & Admin98.89M102.29M87.54M156.61M109.86M
Operating Expenses136.83M153.26M127.05M259.5M135.85M
Depreciation & Amortization15.57M15.03M15.18M16.86M6.98M
EBITDA(44.27M)(173.57M)(54.46M)(118.14M)(89.69M)
EBITDA Margin-33.9%-177.2%-51.2%-67.7%-105.1%
Operating Income(67.46M)(116.21M)(76.6M)(175.24M)(93.31M)
Operating Margin-51.7%-118.6%-72.0%-100.5%-109.3%
Interest Income02.23M5.57M20.2M9.18M
Interest Expense3.82M4.33M4.57M3.32M26K
Other Income / Expenses3.8M(76.72M)2.4M36.92M(3.4M)
Income Before Tax(63.66M)(192.93M)(74.2M)(138.31M)(96.7M)
Pre-Tax Margin-48.8%-197.0%-69.8%-79.3%-113.3%
Income Tax Expense(4.42M)(2.83M)452K573K(37.88M)
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Net Margin-45.4%-194.1%-70.2%-79.6%-87.8%
EPS (Basic)(0.78)(2.43)(0.94)(0.52)(0.20)
EPS (Diluted)(0.78)(2.43)(0.94)(0.52)(0.20)
Weighted Avg Shares75.79M78.31M79.16M352.67M381.62M
Weighted Avg Shares (Diluted)75.79M78.31M79.16M352.67M381.62M

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.